Genentech Summary


    Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines. Its main products are an antibody for cancer and medicine for primary progressive multiple sclerosis.

    HQSouth San Francisco, CA, USMap
    Employee Ratings
    Overall CultureB+More


    Genentech is headquartered in
    South San Francisco, United States

    Location Map

    Latest Updates

    Company Growth (employees)

    Employees (est.) (Oct 2021)20,222
    Job Openings456
    Website Visits (May 2021)220 k(+8%)
    Cybersecurity ratingBMore
    Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

    Key People/Management at Genentech

    Genentech Office Locations

    Genentech has offices in South San Francisco, Hillsboro, Oceanside and Vacaville

    Genentech Financials and Metrics

    Summary Metrics

    Founding Date


    Genentech is a subsidiary of Roche

    Genentech Hiring Categories

    Genentech Median Salaries

    Source: 9 public H-1B filings from Genentech

    Genentech Cybersecurity Score

    Cybersecurity ratingPremium dataset



    SecurityScorecard logo

    Genentech Website Traffic

    Alexa Website Rank

    Total Visits per monthSimilarWeb

    Genentech Online and Social Media Presence

    Twitter followers

    122.03 k Twitter followers

    6 Months

    Genentech has 122.03 k Twitter Followers. The number of followers has increased 0.37% month over month and increased 0.68% quarter over quarter.

    Genentech's Trends

    Search term - Genentech

    Twitter Engagement Stats for @genentech

    • 7.3 k


    • 240


    • 122.03 k


    • 39

      Tweets last 30 days

    • 14.1

      Avg. likes per Tweet

    • 84.6%

      Tweets with engagement

    Genentech Technology StackBuildWith Logo

    • ads

      5 products used

      • Bizo
      • DoubleClick.Net
      • Facebook Custom Audiences
        • LinkedIn Ads
        • Twitter Ads
    • analytics

      29 products used

      • Adobe Dynamic Tag Management
      • Adobe Marketing Cloud
      • Bizo Insights
        • BlueConic
        • Cloudflare Insights
        • CrazyEgg
        • Eloqua
        • Facebook Conversion Tracking
        • Facebook Domain Insights
        • Facebook Pixel
        • Facebook Signal
        • FullStory
        • Global Site Tag
        • Google Analytics
        • Google Analytics Classic
        • Google Analytics IP Anonymization
        • Google Universal Analytics
        • GoSquared
        • Hotjar
        • LinkedIn Insights
        • New Relic
        • Omniture SiteCatalyst
        • Pingdom RUM
        • Quantcast Measurement
        • Report URI
        • Salesforce
        • Twitter Analytics
        • Twitter Conversion Tracking
        • Twitter Website Universal Tag
    • CDN

      15 products used

      • AJAX Libraries API
      • Akamai
      • Amazon S3
        • BootstrapCDN
        • CDN JS
        • Cloudflare
        • Cloudflare JS
        • CloudFront
        • Content Delivery Network
        • GStatic Google Static Content
        • jQuery CDN
        • jsDelivr
        • MaxCDN
        • OSS CDN
        • Twitter CDN
    • cdns

      4 products used

      • Amazon CloudFront
      • Amazon S3 CDN
      • Cloudflare CDN
      • MaxCDN Verified CDN
    Learn more on BuiltWith

    Genentech Company CultureCultureAndCompensation Logo

    • Overall Culture



    • CEO Rating



    • Compensation



    • Diversity



    Learn more on Comparably

    Genentech News and Updates

    May 25, 2021
    Pieris stock rockets on record volume after Genentech collaboration valued at up to $1.4 billion
    _3xOCqShares of Pieris Pharmaceuticals Inc. rocketed 57.3% on massive volume in afternoon trading Tuesday, after the Boston-based biotechnology company announced a respiratory and ophthalmology collaboration with Roche Holding AG's Genentech that could be valued at more than $1.4 billion. Trading volume spiked to a record 205.7 million shares, enough to make the stock the most actively traded on major U.S. exchanges, and compared with the full-day average of about 576,200 shares, according to FactSet. The collaboration and license agreement with Genentech is to discover, develop and commercialize respiratory and ophthalmology therapies using Pieris's Anticalin technology. Under terms of the collaboration, Pieris will receive an upfront payment of $20 million, and is eligible to receive more than $1.4 billion in additional milestone payments plus royalties for commercialized programs. Pieris recorded revenue of $29.3 million in 2020, down from $46.3 million in 2019. Pieris' part in the collaboration is discovery research and early preclinical development of the programs, while Genentech will be responsible for investigational new drug (IND)-enabling activities, clinical development and commercialization. The stock has now gained 16.4% year to date, while the iShares Nasdaq Biotechnology ETF has slipped 0.9% and the S&P 500 has advanced 11.8%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.
    Apr 07, 2021
    Genentech CEO Alexander Hardy: COVID-19 means being ‘fast and flexible’
    _3xOCqBut how can Big Pharma maintain these skills? Read More
    Mar 12, 2021
    Insights on the Alzheimer's Disease Drugs Global Market to 2027 - Featuring Allergen, Biogen and Genentech Among Others
    DUBLIN, March 12, 2021 /PRNewswire/ -- The "Alzheimer's Disease Drugs - Global Market Trajectory & Analytics" report has been added to's offering. Amid the COVID-19 crisis, the global market for Alzheimers Disease Drugs estimated at US$ 5.9 Billion in the year 2020,...
    Dec 01, 2020
    Cervical Cancer Treatment Market Driven By Top Companies Biocon Limited, Advaxis, Genentech
    Cervical cancer is the uncontrollable growth of tumor in the cervix, the condition is recognized by symptoms such as, abnormal vaginal discharge, abnormal vaginal bleeding and pelvic pain. Posted via Industry Today. Follow us on Twitter @IndustryToday
    Nov 23, 2020
    OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites
    NASHVILLE, Tenn., Nov. 23, 2020 /PRNewswire/ -- OneOncology, the national partnership of independent oncology practices, and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the first clinical trial available to patients through OneR, the OneOncology...
    Nov 20, 2020
    Howard University Student Pharmacist Presents Critical Research Following the Conclusion of AMCP Foundation and Genentech Internship
    ALEXANDRIA, Va., Nov. 20, 2020 /PRNewswire/ -- AMCP Foundation recognizes Montrell Taylor, 2021 PharmD Candidate at Howard University College of Pharmacy, for his successful completion of the Genentech Evidence for Access Summer Internship Program. Now in its seventh year, the AMCP...

    Genentech Blogs

    Oct 14, 2021
    Q&A: Managing Idiopathic Pulmonary Fibrosis (IPF)
    Dr. Sachin Gupta discusses IPF, ongoing research and predictions for the future....
    Sept 29, 2021
    The Subtle Signs of AML
    The easy-to-miss symptoms that led a former nurse and patient advocate to her father's AML diagnosis....
    Sept 29, 2021
    Innovative treatment and research approaches offer new hope for those with blood cancer
    Learn about key advances in recent years and where the field is headed, including perspective from Dr. Nancy Valente. While Dr. Valente was an employee at the time this article was written, she has since left Genentech....
    Sept 22, 2021
    Inequity Interventions
    Patients want change; providers agree—we need to disrupt the status quo....
    Sept 15, 2021
    Demystifying MS: The Intersection Of Immunology And Neuroscience
    Featuring Ann Herman, Senior Director and Senior Principal Scientist, OMNI-BD Inflammation and Infectious Disease, and Tracy Yuen, Senior Scientist and Biology Team Lead, Neuroscience....
    Sept 02, 2021
    Connecting the Dots in Alzheimer’s Disease
    Biomarkers are helping to unveil a bigger picture of this complex condition....

    You may also be interested in Related companies

    Strides Pharma
    Bengaluru, IN
    Strides Pharma Science (formerly known as Strides Shasun) is a pharmaceutical company with a focus on the development and manufacture of IP-led niche finished dosage formulations.
    View company
    China Biologic Products
    null, CN
    China Biologic Products is a company focused on the plasma-based biopharmaceutical industry.
    View company
    Alembic Pharmaceuticals
    12160  5increase
    Alembic Pharmaceuticals is a company that manufactures branded formulations, international generics, and APIs (active pharmaceutical ingredients).
    View company
    BioMarin Pharmaceutical
    San Rafael, US
    3001  5increase
    BioMarin develops and provides innovative biopharmaceuticals for serious diseases and medical conditions.
    View company
    When was Genentech founded?
    Genentech was founded in 1976.
    Who are Genentech key executives?
    Genentech's key executives are Severin Schwan, Alexander Hardy and Herbert W. Boyer.
    How many employees does Genentech have?
    Genentech has 20,222 employees.
    Who are Genentech competitors?
    Competitors of Genentech include Allergan, Opthea and Biogen.
    Where is Genentech headquarters?
    Genentech headquarters is located at 1 DNA Way, South San Francisco.
    Where are Genentech offices?
    Genentech has offices in South San Francisco, Hillsboro, Oceanside and Vacaville
    How many offices does Genentech have?
    Genentech has 4 offices.

    Craft real-time company insights

    Learn about Craft real-time company insights

    Receive alerts for 300+ data fields across thousands of companies

    Footer menu